Company Overview

About IDx

IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous AI systems that detect disease in medical images. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection.

The company's first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy.

IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer's disease, cardiovascular disease, and stroke risk.

At a Glance

Company Name: IDx Technologies Inc.

Headquarters: Coralville, IA U.S.

Founded: 2010

Employees: 63

Mission: To transform the quality, accessibility, and affordability of global healthcare through the automation of medical diagnosis and treatment

Founder and CEO: Dr. Michael D. Abramoff

Executive Chairman: Gary Seamans

Total Funding to Date: $54.7M

Strategic Investors: 8VC, Optum Ventures, Alpha Edison, Heritage Provider Network

www.eyediagnosis.net

IDx-DR: FDA-cleared autonomous AI

• Enables non-eye care providers to administer a diabetic retinopathy exam

• No specialist overread and no telemedicine required

• Exam takes less than 10 minutes

• Completed by staff member of any education level

• Immediate diagnostic results at the point of care

• System includes all components needed for easy placement in retail and primary care clinics:

    o A smart robotic retinal camera

    o Highly accurate AI-based diagnostic algorithm

    o Interactive AI to guide the operator

    o Easy to use operator interface

    o Comprehensive user training program

IDx Timeline

• **2010:** AI diagnostics company IDx founded by Dr. Abramoff with several colleagues from University of Iowa Health Care

• **2013:** IDx-DR approved for sale in Europe

• **January 2017:** Clinical trial of IDx-DR launches in primary care sites around the U.S.

• **February 2018:** IDx files De Novo submission to Food and Drug Administration for expedited review of IDx-DR, which earlier was granted an FDA "Breakthrough Device" designation

• **April 2018:** IDx-DR earns FDA clearance

• **June 2018:** IDx-DR begins testing patients at Diabetes and Endocrinology Center at UI Health Care-Iowa River Landing in Coralville, Iowa

• **August 2018:** Results of IDx-DR clinical trial published in *Nature Digital Medicine*

• **September 2018:** IDx secures $33 million in venture capital funding to develop more diagnostic systems for its AI platform

• **October 2018:** IDx signs exclusive U.S. AI platform agreement with Topcon, a leading ophthalmic device manufacturer

• **February 2019:** IDx-DR sees adoption expand across a number of healthcare settings, including endocrinology clinics, internal medicine clinics, diabetes education centers, and more.

• **June 2019:** The AMA's CPT Editorial Panel accepts a new category 1 CPT code facilitating reimbursement of the IDx-DR exam